CADPT17A12201

• Research type

  Research Study

• Full title

  A multicenter, randomized, double-blind, placebo-controlled, Phase II platform study to assess the efficacy and safety of GHZ339 and other biologic compound(s) in patients with moderate to severe atopic dermatitis.

• IRAS ID

  1011451

• Contact name

  Fiona Morris

• Contact email

  fiona.morris@novartis.com

• Sponsor organisation

  Novartis Pharmaceuticals UK Ltd.

• Clinicaltrials.gov Identifier

  NCT06947993

• Research summary

  The purpose of this trial is to learn more about the effects of new treatments in people with moderate to severe atopic dermatitis (AD). This trial will start with testing the effects of GHZ339 compared with placebo in moderate to severe atopic dermatitis (AD). Other new treatments will be added, later, to this trial for testing in patients with moderate to severe AD.

• REC name

  London - Surrey Borders Research Ethics Committee

• REC reference

  25/LO/0472

• Date of REC Opinion

  19 Aug 2025

• REC opinion

  Further Information Favourable Opinion